



PATENT Attorney Docket No. P05375US1

> NOV 0 1 2002 TECH CENTER 1600/2904

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

The Pennsylvania State University

Group Art Unit: 1632

SERIAL NO:

10/006,403

Examiner:

FILED:

December 5, 2001

Confirmation No: 4264

TITLE:

A MONOCLONAL ANTIBODY-BASED

DIAGNOSTIC ASSAY FOR GAMMA FIBRINOGEN

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. The Examiner is requested to consider the references and make them of record. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No. 60/251,291, filed on December 5, 2000. This application also relies, under 35 U.S.C. § 120, on the earlier filing date of prior PCT application Serial No. PCT/US01/47208, filed on December 5, 2001. The following references were submitted to, and/or cited by, the Patent Office in the prior application(s) and, therefore, are not required to be provided in this application: (U.S. Documents: Humes, et al.; Mosesson, et al.; Altieri et al.; Soe et al.; Edwards et al.; Ginsberg, Mark H.; Kraus et al.; Flow et al.; Frelinger, III et al.; Fickenscher, Karl; Ginsberg, Mark H.; Bundesen et al.; Kudryk et al.; Hawiger et al.; and Hawiger, et al.; Foreign Patent Documents: 2-84175 Japanese Patent 1990; PCT/US87/02125

CERTIFICATE OF MAILING

I hereby certify that the above correspondence was mailed to the Assistant Commissioner for Patents, Washington, D.C. 20231, as First Class mail, postage prepaid, this 2 day of October, 2002.

Wendy K. Marsh

March 10, 1998, American Biogenetic Sciences, Inc., Ploplis, et al.; and *Other – Non-Patent Documents*: Drouet et al.; "Plasma y'/y fibrinogen ratio, a marker of arterial thrombotic activity: a new potential cardiovascular risk factor?"; Blood Coagulation and Fibrinolyss 1999 Vol. 10 (suppl 1); pages S35 – S39; Lippincott Williams & Wilkins; Paris, France.)

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A and 08B (formerly Form PTO-1449) accompany this information statement.

y

Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Authorization is hereby made to charge any additional fees required by this paper or credit any overpayment to Deposit Account 26-0084. A duplicate of this paper is attached.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,

Wendy K. Marsh, Reg. No. 39,705 McKEE, OORHEES & SEASE, P.L.C.

801 Grand Avenue, Suite 3200

Des Moines, Iowa 50309-2721

Phone No. (515) 288-3667

Fax No. (515) 288-1338

CUSTOMER NO: 22885

- jc -Attorneys of Record

'n

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of Sheet

Complete if Known			
Application Number	10/006,403		
Filing Date	December 5, 2001		
First Named Inventor	Farrell, David H.		
Art Unit	1632		
Examiner Name			
Attorney Docket Number	P05375US1		

	U.S. PATENT DOCUMENTS				
Examiner Initials *	Cite No.¹	<u>Document Number</u> . Number - Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
· · · · · ·					
					NED
					CEIVE
					PECEIVED NOV 0 1 2002 TECHCENTER 180018
					100 0 100
				·	1000 CB 1600
					CENIE!
					TECHO
					<u> </u>
	ļ				

FOREIGN PATENT DOCUMENTS					
Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	т•
	FR 27 769 093 A	09-30-1997	PASTEUR SANOFI DIAGNOSTICS	Pg 7, line 24 – line 31; claim 8; example 1	
		<u> </u>			
		Cite No.¹ Foreign Patent Document Country Code³ -Number⁴- Kind Code⁵(if known)	Cite No.¹ Foreign Patent Document Country Code³ -Number⁴- Kind Code⁵ (if known) Publication Date MM-DD-YYYY	Cite No.! Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document	Cite No.¹ Toreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages or Relevant Passages or Relevant Figures Appear

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional)... 2 See Kinds of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated

on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Form PTO/SB/08B (10-01) toved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and mark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of

Complete if Kn wn			
Application Number	10/006,403		
Filing Date	December 5, 2001		
First Named Inventor	Farrell, David H.		
Group Art Unit	1632		
Examiner Name			
Attorney Docket Number	P05375US1		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		HAIDARIS P J ET AL: "Megakaryocyte and Hepatocyte Origins of Human Fibrinogen Biosynthesis Exhibit Hepatocyte-Specific Expression of Gamma Chain-Variant Polypeptides" Blood, Vol. 74, No. 2, 1989, pgs. 743-750, XP001105248		
		HAIDARIS P J ET AL: "The Carboxyl-Terminal Sequences of the Gamma-57.5 Chain of Human Fibrinogen Constitute A Plasmin Sensitive Epitope that is Exposed in Crosslinked Fibrin" Blood, vol. 74, no. 7, 1989, pages 2437 – 2444, XP002070838		
		, ED		
		ECENER		
		RECEIVED NOV 0 1 2002 TECH CENTER 1600	200	
		CENTER 1600		
		TEUT		
	;			

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*} EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.